← All companies

NVST · CIK 1757073

What Envista Holdings Corporation told the SEC could break it.

Envista's disclosures cluster on trade and pricing pressures squeezing a dental-products business. Increased import tariffs raised its cost of sales in 2025 and helped push operating margin down from 17.0% to 16.3%, alongside unfavorable currency and mix. In its China business (about 7% of annual sales), the government's volume-based procurement reforms have driven significant price cuts for medical and dental consumables, eroding pricing there. And for certain components that need particular specifications, it relies on a single or limited number of suppliers, which could cause production interruptions and delays.

3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.

In its own words

What could break it.

Regulatory & policy

  • import tariffs (realized cost-of-sales & margin impact)medium

    Increased tariffs contributed to higher cost of sales in 2025 and pressured operating profit margin (17.0% to 16.3%), alongside unfavorable FX and product mix.

    The increase in cost of sales during the year ended December 31, 2025, as compared to the comparable period in 2024, was driven primarily by higher sales volume, higher costs due to the unfavorable impact of foreign currency exchange rates, and increased tariffs, partially offset by the absence of impairment related to certain long-lived assets from the comparable prior period.

  • China volume-based procurement (VBP) price controlsmedium

    China's volume-based procurement (VBP) centralized reforms have driven significant price cuts for medical and dental consumables, reducing pricing in Envista's China business (~7% of annual sales).

    For example, China has implemented volume-based procurement (“VBP”) policies, a series of centralized reforms instituted in China on both a national and regional basis that has resulted in significant price cuts for medical and dental consumables.

    SEC filing →As of 2026

Sole-source dependency

  • single/limited-source specialized componentslow

    For certain components requiring particular specifications or qualifications, Envista relies on a single supplier or limited number of suppliers, which could cause production interruptions, delays and inefficiencies.

    For certain components that require particular specifications or qualifications there may be a single supplier or a limited number of suppliers that can readily provide such components.

    SEC filing →As of 2026

The hidden graph

Who it depends on, and who depends on it.

Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.

Its customers

  • Henry Schein, Inc.

    One customer, Henry Schein, Inc. (“Henry Schein”), accounted for approximately 12% of our sales for 2025 and 10% of our sales for 2024 and 2023.

    Cited →

In the MyPRIA app, this is checked against the companies you actually own.

← World Watch